The Trump administration's One Big Beautiful Bill Act has proposed significant Medicaid funding reductions, representing the largest in history and presenting alarming challenges for rural healthcare systems. With estimates suggesting that over 10 million Americans could lose coverage, the
In a groundbreaking development for pediatric oncology, the U.S. Food and Drug Administration (FDA) has approved a clinical trial for Reyobiq (Rhenium Re186 Obisbemeda), a promising radiation therapy aimed at treating aggressive brain tumors in children. This trial has generated significant
The healthcare sector is undergoing a significant transformation as its organizations increasingly face intense scrutiny from federal audit bodies, particularly those linked to Medicare and Medicaid. This new era of healthcare audits prompts hospitals, clinics, and care facilities to re-evaluate
The European Health Data Space (EHDS) regulation represents a monumental shift in handling health data across the European Union, endeavoring to create a unified registry that could revolutionize healthcare access and research capabilities. Central to its successful implementation is the element of
In the ever-evolving field of oncology, Bristol Myers Squibb has made waves with its strategic expansion into radiopharmaceuticals for prostate cancer. Leading this charge is the promising compound, OncoACP3, developed in collaboration with Philochem. Here to talk about these exciting developments
The landscape of surgical intervention is continuously evolving, and Levita Magnetics is at the forefront of this transformation with its recent expansion of the MARS (magnetic-assisted robotic surgery) system. With expanded FDA 510(k) clearance, MARS and its Magnetic Surgical System (MSS) are now
